PROTHENA CORP PLC

Prothena insider trades reveal short‑term moves by William Scully—fast buy‑sell, high cash burn, and a cautious outlook for the antibody platform.

Insider buying of Prothena shares signals confidence in its antibody pipeline and potential upside as clinical milestones arrive.

Prothena’s insider buying surge shows senior execs backing its antibody pipeline—warranting a closer look for investors seeking next‑stage biotech upside.

Prothena insider buying spikes as CEO William Scully buys 125K shares amid market volatility, signaling confidence in its Alzheimer’s drug pipeline and potential upside.

PROTHENA’s insider confidence, strong social‑media buzz, and strategic antibody pipeline suggest a promising future in Alzheimer’s therapeutics, but investors must weigh current valuation risks and market dynamics.